View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
April 24, 2020

First Scottish-led trial to assess Insmed’s brensocatib for Covid-19

Researchers at The University of Dundee in Scotland, UK are set to lead a clinical trial of Insmed’s brensocatib (formerly INS1007) for the treatment of Covid-19 patients.

Insmed will provide funding and supply the drug, which is being developed to treat lung inflammation in bronchiectasis and other inflammatory conditions.

The new trial, called STOP-COVID19, will assess the drug’s ability to decrease the incidence of acute lung injury and prevent mechanical ventilation in up to 300 hospitalised patients at ten sites across the UK.

Read the full article here

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena